ADHD drug cardiac safety
Executive Summary
FDA's Drug Safety & Risk Management Advisory Committee will discuss studies to assess the risk of adverse cardiovascular outcomes with drugs for attention deficit/hyperactivity disorder on Feb. 9. Adderall XR added warnings about cardiovascular events in certain patients in 2004 and the drug was suspended by Health Canada for several months in 2005. FDA has been looking at psychiatric and cardiovascular events across the entire category of ADHD drugs, which include J&J's Concerta, Novartis' Ritalin and Focalin, and Lilly's Strattera (1"The Pink Sheet" Oct. 3, 2005, p. 8). The meeting will take place at the Holiday Inn in Gaithersburg, Md., beginning at 8 a.m. [Editor's note: To 2watch a webcastor order a video/DVD of this and other meetings, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
ADHD Suicidal Thinking Health Advisory Limited To Lilly’s Strattera
FDA does not intend to release a general public health advisory for attention deficit/hyperactivity disorder medications despite issuing one for Lilly's Strattera (atomoxetine) Sept. 29
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.